Investigational Therapies, Modalities May Change Recurrent C Difficile Treatment Trajectory


During the C Diff Foundation's Annual conference, providers and stakeholders offered insights on the latest investigational therapies and modalities as they advance through clinical trials.

Video Highlights

1:25 Paul Feuerstadt, MD, FACG, AGAF

3:16 Dale Gerding, MD, FACP, FIDSA

5:21 Glenn Tillotson, PhD, FIDSA, FCCP

Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.

In this episode, our 1 Big Question is: Recurrent C difficile has been a clinical challenge. What more can be done to address it?

We interviewed presenters from the 9th Annual International C. Diff Conference & Health EXPO, including Conference Co-Chair and Keynote Speaker Paul Feuerstadt, MD, FACG, AGAF, attending gastroenterologist, PACT Gastroenterology Center, Dale Gerding, MD, FACP, FIDSA, professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and research physician at the Edward Hines Jr. VA Hospital, and Glenn Tillotson, PhD, FIDSA, FCCP, GST Micro LLC.

Check out our video to hear their insights.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.